Table 1. Characteristics of women receiving HAART at conception and the available measurements on these women during pregnancy.
| Women (n=127) | |
|---|---|
|
| |
| n (%)† | |
| Type of HAART regimen | |
| Pi-containing | 78 (61) |
| NNRTI-containing | 49 (39) |
| Race by IDU status | |
| Black non-IDU | 37 (32) |
| White non-IDU | 47 (41) |
| White IDU | 31 (27) |
| Other | 12 |
| Age at delivery (years) | |
| Median (IQR) | 33 (30-37) |
| 18-25 | 10 (8) |
| 26-34 | 63 (53) |
| ≥35 | 46 (39) |
| Unknown | 8 |
| Time period of delivery | |
| 1998-1999 | 21 (16) |
| 2000-2001 | 49 (38) |
| 2002-2003 | 49 (38) |
| 2004-2006 | 8 (6) |
| Duration of HAART at time of conception | |
| Median months (IQR) | 10 (5, 20) |
| ≥ 15 months | 42 (33) |
| 6-15 months | 41 (32) |
| < 6 months | 44 (35) |
|
| |
| Measurements (n=371) | |
|
| |
| n (%)† | |
|
| |
| Median baseline VL* (log10 copies/ml) (IQR) | 3.22 (2.61-3.92) |
| No. of undetectable measurements | |
| Total | 79/363 (22) |
| First trimester | 1/74 (1) |
| Second trimester | 23/140 (16) |
| Third trimester | 36/100 (35) |
| Delivery | 21/50 (42) |
| Median VL at delivery (log10 copies/ml) (IQR) | 2.45 (1.45-2.99) |
| Median VL at delivery among detectable | 2.89 (2.57-3.48) |
| HIV RNA assay | |
| Roche | 270 (73) |
| Other | 107 (27) |
| Median baseline* CD4 count (cells/mm3) (IQR) | 380 (288-517) |
†
- unless other stated
*
at first pregnancy measurement
Abbreviations: IQR, interquartile range; VL, VL; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor